Skip to content

Prospective Randomized Non-Inferiority Study Comparing Natural Cycle Frozen Embryo Transfer (NC-FET) to a New Type of Endometrial Preparation for FET: Natural Proliferative Phase (NPP-FET)

Prospective Randomized Non-Inferiority Study Comparing Natural Cycle Frozen Embryo Transfer (NC-FET) to a New Type of Endometrial Preparation for FET: Natural Proliferative Phase (NPP-FET)

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06859944
Acronym
NPP
Enrollment
272
Registered
2025-03-05
Start date
2024-08-05
Completion date
2026-06-30
Last updated
2025-03-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Comparison of Pregnancy Rate (HCG+ Level) Obtained After a Replacement Embryonic in Spontaneous Cycle and Following Protocol NPP. Comparison

Brief summary

Frozen embryo replacement cycle :Two methods traditionally used: the spontaneous cycle and the artificial cycle.Now, Emergence of new protocols: NPP-FET or Natural proliferative phase - frozen embryo transfer Demonstrate non-inferiority between the NPP-FET and the spontaneous cycle, and superiority in terms of planning.

Detailed description

The protocol Natural proliferative phase/Natural Programmed by Progesterone, Patients with regular cycles, candidates for replacement of embryos frozen in a spontaneous cycle. The monitoring of the cycle is carried out by taking blood and follicular ultrasound between the 10th and 13th day of the cycle. Support luteal phase by intravaginal progesterone (utrogestan 200 mg) 1 tablet, 2 times per day, is initiated once the following criteria are met: * Thickness of the endometrium \> 7 mm on ultrasound * Ovarian follicle \> 14 mm * Estradiol( E2) \> 120 pg/mL Embryo transfer is scheduled on the 6th day of progesterone exposure exogenous. A progesterone dosage on the day of transfer will be systematically realized

Interventions

OTHEREmbryo transfer

Frozen embryo transfer

Sponsors

Erasme University Hospital
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 45 Years
Healthy volunteers
No

Inclusion criteria

* Single transfer Blastocyste

Exclusion criteria

* PGT (Preimplantation genetic diagnosis) * Testicular Sperm * Donor oocytes

Design outcomes

Primary

MeasureTime frame
Comparison of the pregnancy rate (Human chorionic gonadotropin hormone) (HCG+ level) obtained after spontaneous embryo replacement and following the NPP protocol.Thrugh study completion (9 months)

Countries

Belgium

Contacts

Primary ContactAnne Delbaere
anne.delbaere@hubruxelles.be+32 2 555 45 70

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026